Expertise in
8
conditions

Sarah J. Jefferies

Hills Road, CB2 0QQ, 
Cambridge, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Hills Road, CB2 0QQ, 
Cambridge, ENG, GB 

Overview

Sarah Jefferies practices in Cambridge, United Kingdom. Ms. Jefferies is highly rated in 8 conditions, according to our data. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Gliomatosis Cerebri, and Thyroidectomy.

Her clinical research consists of co-authoring 59 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Hills Road, CB2 0QQ, Cambridge, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Radiation, Drug
Study Drug: AZD1390
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.
A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2025
Intervention Type: Radiation, Drug
Study Drugs: 2-hydroxyoleic Acid, Temozolomide
Study Phase: Phase 2/Phase 3
Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2024
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1-10 Brain Metastases
A Randomized Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1-10 Brain Metastases
Enrollment Status: Completed
Publish Date: February 25, 2021
Intervention Type: Radiation
Study Phase: Phase 2
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma
Enrollment Status: Completed
Publish Date: February 05, 2018
Intervention Type: Drug, Procedure, Genetic, Other
Study Phase: Phase 1
View 4 Less Clinical Trials

59 Total Publications

Radiotherapy for Growing Vestibular Schwannomas.
Radiotherapy for Growing Vestibular Schwannomas.
Journal: JAMA otolaryngology-- head & neck surgery
Published: September 04, 2025

Frequently Asked Questions about Sarah J. Jefferies

Is Sarah J. Jefferies a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Sarah J. Jefferies is classified as an Distinguished expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sarah J. Jefferies participate in research or clinical trials?

Yes. Sarah J. Jefferies has published 59 articles and abstracts on conditions like Glioblastoma. You can view a list of Sarah J. Jefferies's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Jefferies's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile